GILD vs KURA
GILD: A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis, and cancer. KURA: Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships.
Side-by-side fundamentals
| Metric | GILD | KURA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $130.34 | $10.54 | |
| Market cap as of 2026-07-23 | $163.6B | $944M | |
| P/E as of 2026-07-23 | 17.75 | n/a | |
| PEG as of 2026-07-23 | 1.94 | -0.05 | KURA lower |
| Net margin as of 2026-07-23 | +31.0% | -411.2% | GILD higher |
| Gross margin as of 2026-07-23 | +79.3% | +99.9% | KURA higher |
| Operating margin as of 2026-07-23 | +34.9% | -443.5% | GILD higher |
| ROE as of 2026-07-23 | +42.2% | -141.9% | GILD higher |
| ROA as of 2026-07-23 | +16.1% | -43.3% | GILD higher |
| Debt / equity as of 2026-07-23 | 0.94 | 0.09 | KURA lower |
| Revenue growth (YoY) as of 2026-07-23 | +3.5% | +29.5% | KURA higher |
| Revenue CAGR (3y) SEC XBRL | +2.6% | n/a | |
| Dividend yield as of 2026-07-23 | +2.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.34 | 0.37 | |
| 1-year return as of 2026-07-22 close | +18.3% | +58.0% | KURA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.